title: Improved intradialytic stability during haemodialysis with blood volume-controlled ultrafiltration.
abstract: BACKGROUND
  Intradialytic morbid events (IMEs) during haemodialysis (HD), including symptomatic hypotension, are related to ultrafiltration (UF)-induced hypovolaemia. Blood volume monitoring and automatic feedback control of the UF rate were developed to limit the extent of hypovolaemia during dialysis. The present study investigated the effect of blood volume (BV)-controlled UF on the incidence of HD treatments with IMEs.
  
  
  METHODS
  This prospective randomised crossover study included hypotension-prone patients, characterised by occurrence of IMEs in at least 33% of HD treatments during a 6-week screening phase. These patients underwent 2 treatment phases, each lasting 6 weeks, in randomised order. Each patient served as their own control, treated with standard HD in one phase and with BV-controlled UF in the other phase.
  
  
  RESULTS
  Thirty-four patients from 9 HD centres were enrolled; 26 could be included in the analysis population. In comparison with standard HD, BV-controlled UF reduced the percentage of HD sessions complicated by IME significantly from 40%+/-27% to 32%+/-25% (p=0.02). A lower frequency of HD sessions with IME could be observed in 46% of the patients. The frequency of treatments with symptomatic hypotension was reduced from 32%+/-23% in standard HD to 24%+/-21% with BV-controlled UF (p=0.04). Changes in blood pressure and heart rate from start to end of the HD session were not different between the 2 treatment modes.
  
  
  CONCLUSIONS
  This crossover study showed improved intradialytic stability with BV-controlled UF, compared with standard HD.
authors.affiliation: Hospital of Valle d'Aosta, Aosta, Italy.
authors.forename: Danila
authors.initials: D
authors.lastname: Gabrielli
authors.forename: Batya
authors.initials: B
authors.lastname: Krystal
authors.forename: Krassimir
authors.initials: K
authors.lastname: Katzarski
authors.forename: Maan
authors.initials: M
authors.lastname: Youssef
authors.forename: Toufic
authors.initials: T
authors.lastname: Hachache
authors.forename: Frantisek
authors.initials: F
authors.lastname: Lopot
authors.forename: Catherine
authors.initials: C
authors.lastname: Lasseur
authors.forename: Thomas
authors.initials: T
authors.lastname: Gunne
authors.forename: Branimir
authors.initials: B
authors.lastname: Draganov
authors.forename: Ralf
authors.initials: R
authors.lastname: Wojke
authors.forename: Adelheid
authors.initials: A
authors.lastname: Gauly
mesh_terms: D000368:Aged; D001810:Blood Volume / Q000502:physiology*; D001811:Blood Volume Determination; D018592:Cross-Over Studies; D005260:Female; D005440:Fluid Therapy / Q000379:methods*; D005500:Follow-Up Studies; D006801:Humans; D006982:Hypertonic Solutions / Q000008:administration & dosage; D007022:Hypotension / Q000209:etiology / Q000503:physiopathology* / Q000517:prevention & control; D007024:Hypotension, Orthostatic / Q000209:etiology / Q000503:physiopathology* / Q000517:prevention & control; D020896:Hypovolemia / Q000150:complications / Q000503:physiopathology* / Q000628:therapy; D007262:Infusions, Intravenous; D007552:Isotonic Solutions / Q000008:administration & dosage; D008297:Male; D011446:Prospective Studies; D006435:Renal Dialysis / Q000009:adverse effects* / Q000379:methods; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D006982:Hypertonic Solutions; D007552:Isotonic Solutions